Diaco Biotechnologies

Diaco Biotechnologies is an Argentine biotechnology company specializing in the development and large-scale production of high-complexity biological medicines, with a primary focus on biosimilar monoclonal antibodies. Based in Buenos Aires, the company operates a state-of-the-art manufacturing facility in Zárate equipped with advanced single-use bioreactor technology for cell culture and protein purification. Diaco aims to improve access to advanced therapies in Latin America by providing high-quality, cost-effective alternatives to reference biologics for oncology and inflammatory diseases. Their portfolio includes biosimilar versions of major treatments such as rituximab and bevacizumab, produced under strict international Good Manufacturing Practices (GMP) standards. The company is recognized as one of the few regional players capable of managing the entire bioprocessing cycle from cell bank development to final product fill and finish.